By Ian Cassel : A very important shot was fired last week in the battle for the colorectal cancer diagnostics market. Cancer diagnostics minnow VolitionRx (OTCQB: VNRX ) announced the first tranche of data from its retrospective clinical trial with Hvidovre Hospital in Copenhagen, Denmark. The ...
Exact Sciences ( EXAS +7.3% ) is up again in early trading. Shares have more than doubled from the May 8, 2014 low of $10.69. The FDA approved
The Mayo Clinic will offer Exact Sciences ' ( EXAS +4.8% ) Cologuard as a screen for colorectal cancer. The test will be available to patients through their primary care physicians. It is the first health system to sign on to offer the test. Post your comment!
By Andy Batts : Exact Sciences (NASDAQ: EXAS ) has bagged FDA approval for ..... colorectal cancer. Upon approval, Exact Sciences instantly received a proposed ..... healthcare providers for $599. Exact Sciences CEO Kevin Conroy told FierceMedicalDevices
Gainers: ICPT +45% . FRF +40% . INSY +15% . SUPN +14% . EXAS +8% . CNAT +8% . ARTX +6% . Losers: DNDN -23% . GALE -12% . CALL -10% . NUAN -9% . TKMR -8% . FLO -8% . HCLP -5% . Post your comment!
* U.S. Food and Drug Administration has approved Exact Sciences ' cologuard stool-DNA-based, non-invasive colorectal cancer screening test
The FDA clears Exact Sciences ' ( EXAS +2.5% ) Cologuard , a stool-based colorectal screening test ..... proposes to cover the cost of the test once every three years. EXAS shares are up 4% AH on average volume. Post your comment!
ancillary-benefit suppliers MET, UNM ; PBMs CVS, ESRX ; managed-care providers AET, UNH, CI ; pg 17]; Exact Sciences [ EXAS ; impending FDA approval of its colon cancer screening test; pg 19]; REITs with DC office exposure [ BDN
Dakota and Western Canada should grow 10% per year over the next 3 years. In our opinion, North D akota, O klahoma and T exas are critical states from a production, pipeline route, storage and end-market consumption perspective. We believe these
favorable trials of muscular dystrophy drug; pg 18); Viacom ( VIA/VIAB ; pg 21); Brink’s ( BCO ; pg 22); Exact Sciences ( EXAS ; DNA-based Cologuard test trials appear promising; pg 25); Walgreen ( WAG ; 5-yr valuation low; pg 34